Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect Study of PF-07321332/Ritonavir
NCT05129475Phase 1Completed
- Sponsor
- Pfizer
- Start
- Nov 2021
- Primary completion
- Jan 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Nirmatrelvir in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Pfizer. Primary endpoints: Area Under the Plasma Concentration-Time Profile From Time Zero to the Time of the Last Quantifiable Concentration at 48 hours, Area Under the Plasma Concentration-Time Profile From Time Zero to Extrapolated Infinite Time at 48 hours and 1 more. Started Nov 2021; status: completed.
02
Drugs
Nirmatrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05129475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05129475.